(Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and ...

Rapamycin is a drug used to suppress the immune system in transplant patients, but scientists have found that it may have another use. The drug has been shown to have anti-aging properties, despite no ...

Rapamycin is a licensed drug used in cancer treatment. It can inhibit cell growth in post-transplant patients by suppressing the immune response. Currently, much interest is being shown in this ...

A clinical trial is starting to test a drug taken by many so-called longevity enthusiasts. NPR's Allison Aubrey explains why a dentist is leading the research. ALLISON AUBREY, BYLINE: A few years back ...

Dietary restriction has long been one of the most robust, evidence-backed methods to extend lifespan across multiple species. But if the idea of prolonged fasting or reduced calorie intake sounds ...

Researchers anticipated rapamycin would enhance the effects of working out, while also initiating health improvements of its own, but that wasn’t the case.

A few years back, Matt Kaeberlein was diagnosed with a frozen shoulder. "It was really bad," he recalls. He wasn't sleeping well and couldn't throw a ball due to the pain. His doctor recommended ...

Most current medicines are derived from naturally occurring small molecules. Yet the lack of a systematic method for producing diverse nature-inspired small molecules has prevented the development of ...

Rapamycin, a complex macrolide and potent fungicide, immunosuppressant and anticancer agent, is a highly specific inhibitor of mammalian target of rapamycin (mTOR). Rapamycin has been shown to induce ...

I recently listened to a podcast about antiaging drugs for people. Is there something similar for dogs? The promise of ...

Rapamycin has been trending on social media, where biohackers such as Dr. Peter Attia and Bryan Johnson tout it as the “gold standard” for people seeking to live a longer, healthier life. Rapamycin is ...

Palvella Therapeutics Inc. 100% of patients with bleeding at baseline demonstrated a statistically significant improvement on ...